Table 1.

Patient characteristics

Characteristics	n = 51 (%)
Age (years), median, range	71 (42–91)
Gender
Male/Female	18 (35)/33 (65)
Performance status
0–1/2–3	34 (67)/17 (33)
EGFR genotype
Del 19/L858R	33 (65)/18 (35)
Histology
Adenocarcinoma	51 (100)
Stage
IV/Recurrence	42 (82)/9 (18)
Smoking status
Current smoker	16 (31)
Never or former light smoker	35 (69)
Type of prior EGFR-TKI Gefitinib/Erlotinib/Afatinib	35 (69)/11 (22)/5 (10)
Brain metastasis  Positive/Negative	19 (37)/32 (63)
Number of metastatic lesions
1	19 (37)
≥2	32 (63)
Number of prior regimens (Median, range)	2 (1–6)
1	23 (45)
≥2	28 (55)

Abbreviations: EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.